¼¼°èÀÇ À¯ÀüÀÚ ÆíÁý Ä¡·áÁ¦ ½ÃÀå : ±â¼úº°, °³¹ß ´Ü°èº°, Ä¡·á Á¾·ùº°, ÀûÀÀÁõº°, ÃÖÁ¾»ç¿ëÀÚº°, ±¹°¡º°, Áö¿ªº° - »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À², ¿¹Ãø(2025-2032³â)
Gene Editing Therapeutics Market, By Technology, By Development Stage, By Therapy Type, By Disease Indication, By End User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
»ùÇà ¿äû ¸ñ·Ï¿¡ Ãß°¡
º¸°í¼ ÇÏÀ̶óÀÌÆ®
À¯ÀüÀÚ ÆíÁý Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð´Â 2024³â 1,113¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç 2025³âºÎÅÍ 2032³â±îÁö CAGR 147.20%·Î È®´ëµÉ Àü¸ÁÀÔ´Ï´Ù.
À¯ÀüÀÚ ÆíÁý Ä¡·áÁ¦ ½ÃÀå ¿ªÇÐ
ȹ±âÀûÀÎ ÀÓ»ó ½ÂÀΰú Á¤¹ÐÇÑ µµ±¸·Î Ä¡·áÁ¦ äÅà ÃËÁø
Vertex Pharmaceuticals¿Í CRISPR Therapeutics°¡ Á¦ÈÞÇÏ¿© °³¹ßÇÑ °â»ó ÀûÇ÷±¸Áõ¿¡ ´ëÇÑ Ã¹ ¹øÂ° CRISPR ±â¹Ý Ä¡·áÁ¦°¡ ¹Ì±¹ FDAÀÇ ½ÂÀÎÀ» ¹ÞÀ½À¸·Î½á Àü ¼¼°èÀûÀ¸·Î À¯ÀüÀÚ ÆíÁý Ä¡·áÁ¦ÀÇ Ã¤ÅÃÀÌ °¡¼Óȵǰí ÀÖ½À´Ï´Ù. 2023³â ½ÂÀÎÀº À¯ÀüÀÚ ÆíÁýÀÇ ÀÓ»ó Àû¿ëÀ» ÇâÇÑ ¿ª»çÀûÀÎ ÀüȯÁ¡ÀÌ µÇ¾ú½À´Ï´Ù. µ¿½Ã¿¡ ¹Ì±¹ ±¹¸³º¸°Ç¿ø(NIH)Àº Á¤¹Ð À¯Àüü °øÇÐ ¿¬±¸¿¡ ´ëÇÑ ÀÚ±Ý Áö¿øÀ» ´Ã¸®°í, Ç¥Àû ¿Ü ¿µÇâÀÌ ÀûÀº µ¹¿¬º¯À̸¦ ±³Á¤Çϱâ À§ÇÑ ¿°±â±³Á¤ ¹× ÇÁ¶óÀÓ ÆíÁý°ú °°Àº µµ±¸¸¦ Àå·ÁÇϰí ÀÖ½À´Ï´Ù. ¿µ±¹¿¡¼´Â ÀǾàǰ ¹× ÇコÄɾî Á¦Ç° ±ÔÁ¦Ã»(MHRA)ÀÌ À¯ÀüÀÚ ÆíÁý Ä¡·áÀÇ Á¶±â ½É»ç °æ·Î¸¦ °³½ÃÇÏ¿© ÷´Ü Ä¡·á¹ýÀ» ȯÀÚ¿¡°Ô ´õ »¡¸® Á¦°øÇÏ´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº À¯ÀüÀÚ ÆíÁýÀÇ ¾ÈÀüÇϰí È¿À²ÀûÀ̸ç È®Àå °¡´ÉÇÑ Ä¡·áÀû ÀÀ¿ë¿¡ ´ëÇÑ Àü ¼¼°èÀûÀÎ °ü½ÉÀÇ Áõ°¡¸¦ ¹Ý¿µÇϰí ÀÖÀ¸¸ç, À¯Àü¼º Áúȯ, ¾Ï ¹× º¹ÀâÇÑ ÁúȯÀÇ Ä¡·á¸¦ º¯È½Ãų ¼ö ÀÖ´Â ÀáÀç·ÂÀ» °ÈÇϰí ÀÖ½À´Ï´Ù.
À¯ÀüÀÚ ÆíÁý Ä¡·áÁ¦ ½ÃÀå : ÁÖ¿ä ÀλçÀÌÆ®
´ç»çÀÇ ¿¬±¸ ºÐ¼®°¡µéÀÌ °øÀ¯ÇÑ ºÐ¼®¿¡ µû¸£¸é, ¼¼°è ½ÃÀåÀº ¿¹Ãø ±â°£(2025-2032³â) µ¿¾È ¾à 147.20%ÀÇ CAGR·Î ¸Å³â ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
±â¼úº°·Î´Â CRISPRÀÌ 2024³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµÆ½À´Ï´Ù.
°³¹ß ´Ü°èº°·Î´Â 2024³â ÀüÀÓ»óÀÌ 1À§¸¦ Â÷ÁöÇß½À´Ï´Ù.
Ä¡·á À¯Çüº°·Î´Â ü¿Ü À¯ÀüÀÚ ÆíÁýÀÌ 2024³â ÁÖ¿ä Ä¡·á À¯ÇüÀ¸·Î ²ÅÇû½À´Ï´Ù.
ÀûÀÀÁõº°·Î´Â À¯ÀüÀÚ ÁúȯÀÌ 2024³â ÁÖ¿ä ÁúȯÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù.
ÃÖÁ¾»ç¿ëÀÚº°·Î´Â ¹ÙÀÌ¿À Á¦¾àȸ»ç°¡ 2024³â ÁÖ¿ä ÃÖÁ¾»ç¿ëÀÚ·Î ³ªÅ¸³µ½À´Ï´Ù.
Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 2024³â ¸ÅÃâÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù.
À¯ÀüÀÚ ÆíÁý Ä¡·áÁ¦ ½ÃÀå : ¼¼ºÐÈ ºÐ¼®
¼¼°è À¯ÀüÀÚ ÆíÁý Ä¡·áÁ¦ ½ÃÀåÀº ±â¼ú, °³¹ß ´Ü°è, Ä¡·á À¯Çü, Á¦¿Õ¼º, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ª¿¡ µû¶ó ¼¼ºÐȵ˴ϴÙ.
½ÃÀåÀº ±â¼ú¿¡ µû¶ó CRISPR, ZFN, TALEN, ¿°±â±³Á¤, RNA ÆíÁý, CRISPRÀÌ °£Æí¼º°ú °íÈ¿À²·Î ¼±µÎ¸¦ ´Þ¸®°í ÀÖ°í, ZFNÀº ƯÀ̼ºÀ» Á¦°øÇÏÁö¸¸ º¹ÀâÇÑ ¼³°è°¡ ÇÊ¿äÇϸç, TALENÀº À¯ÀüÀÚ ³ì¾Æ¿ô ¿¬±¸¿¡¼ Ç¥Àû Á¤È®µµ·Î Æò°¡µÇ°í ÀÖ½À´Ï´Ù. À¯ÀüÀÚ ³ì¾Æ¿ô ¿¬±¸¿¡¼ÀÇ Ç¥Àû Á¤È®µµ·Î Æò°¡µÇ°í ÀÖÀ¸¸ç, ¿°±â±³Á¤Àº ´ÜÀÏ ¿°±â º¯°æÀ» °¡´ÉÇÏ°Ô Çϰí, RNA ÆíÁýÀº DNA¸¦ º¯°æÇÏÁö ¾Ê°í ÀϽÃÀûÀÎ º¯ÇüÀÌ °¡´ÉÇÕ´Ï´Ù.
½ÃÀåÀº °³¹ß ´Ü°è¿¡ µû¶ó 5°¡Áö Ä«Å×°í¸®·Î ³ª´¹´Ï´Ù. ÀüÀÓ»ó, 1»ó, 2»ó, 3»ó, ½ÂÀÎ ÈÄÀÔ´Ï´Ù. ÀüÀÓ»ó ´Ü°è´Â ¸¹Àº ¼öÀÇ Èĺ¸¹°ÁúÀÌ Á¶»ç ÁßÀ̰í, ÀÓ»ó 1»óÀº ¾ÈÀü¼º ÇÁ·ÎÆÄÀϸµ¿¡ ÃÊÁ¡À» ¸ÂÃß°í, ÀÓ»ó 2»óÀº Ä¡·á È¿°ú¸¦ Á¶»çÇϸç, ÀÓ»ó 3»óÀº Àüü Áý´Ü¿¡ ´ëÇÑ ´ë±Ô¸ð °ËÁõÀ» Æ÷ÇÔÇÕ´Ï´Ù.
À¯ÀüÀÚ ÆíÁý Ä¡·áÁ¦ ½ÃÀå : Áö¿ªº° ºÐ¼®
À¯ÀüÀÚ ÆíÁý Ä¡·áÁ¦ ½ÃÀåÀº ÷´Ü »ý¸í°øÇÐ ÀÎÇÁ¶ó, ±¤¹üÀ§ÇÑ ÀÓ»ó ¿¬±¸ Ȱµ¿, FDA¿Í °°Àº ±â°üÀÇ Áö¿øÀûÀÎ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©·Î ÀÎÇØ ºÏ¹Ì¸¦ ÇʵηΠ°·ÂÇÑ Áö¿ªÀû ¿ªµ¿¼ºÀ» º¸À̰í ÀÖ½À´Ï´Ù. ¹Ì±¹Àº CRISPR ±â¹Ý Ä¡·á¹ýÀÇ ½ÂÀÎ ¹× ÀÓ»ó½ÃÇè¿¡¼ ¼±µÎ¸¦ ´Þ¸®°í ÀÖÀ¸¸ç, °ø°ø ¹× ¹Î°£À¸·ÎºÎÅÍÀÇ ¸·´ëÇÑ ÀÚ±Ý Áö¿øÀ¸·Î °ÈµÇ°í ÀÖ½À´Ï´Ù. ¿µ±¹, µ¶ÀÏ, ½ºÀ§½º µîÀÇ ±¹°¡µéÀÌ Á¤¹ÐÀÇ·á¿¡ Àû±ØÀûÀ¸·Î ÅõÀÚÇϰí ÀÖÀ¸¸ç, EMA¿Í °°Àº ±ÔÁ¦ ±â°üµµ Çõ½ÅÀûÀÎ À¯ÀüÀÚ Ä¡·á¹ýÀ» Á¡Á¡ ´õ ¸¹ÀÌ ¼ö¿ëÇϰí ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾ç, ƯÈ÷ Áß±¹°ú ÀϺ»¿¡¼´Â Á¤ºÎ ÀÌ´Ï¼ÅÆ¼ºê¿Í »ý¸í°øÇÐ ±â¾÷°úÀÇ Á¦ÈÞ¸¦ ÅëÇØ À¯ÀüÀÚ ÆíÁý ¿¬±¸°¡ °¡¼Óȵǰí ÀÖ½À´Ï´Ù. ÀÓ»ó½ÃÇè°ú ±ÔÁ¦ °³Çõ¿¡ ´ëÇÑ Áß±¹ÀÇ Àû±ØÀûÀÎ Âü¿©´Â °æÀï ±¸µµ¸¦ Çü¼ºÇÏ´Â µ¥ µµ¿òÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¶óƾ¾Æ¸Þ¸®Ä«¿Í Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«´Â ¿ª·® ±¸Ãà°ú ¹Ì·¡ À¯ÀüÀÚ Ä¡·á ÅëÇÕÀ» À§ÇÑ ±ÔÁ¦ ¸ðµ¨ Àû¿ë¿¡ ÁßÁ¡À» µÎ¸é¼ Çмú Á¦ÈÞ ¹× ÆÄÀÏ·µ ÇÁ·Î±×·¥À» ÅëÇØ Á¡Â÷ ÀÌ ºÐ¾ß¿¡ ÁøÀÔÇϰí ÀÖ½À´Ï´Ù.
À¯ÀüÀÚ ÆíÁý Ä¡·áÁ¦ ½ÃÀå : °æÀï »óȲ
À¯ÀüÀÚ±³Á¤ Ä¡·áÁ¦ ½ÃÀåÀÇ °æÀï ±¸µµ´Â »ý¸í°øÇÐ ±â¾÷, Á¦¾à ±â¾÷, ¾ÈÀüÇϰí È¿°úÀûÀÎ À¯ÀüÀÚ±³Á¤ Ä¡·áÁ¦ °³¹ßÀ» À§ÇØ ³ë·ÂÇÏ´Â Çмú ¿¬±¸±â°üÀÌ È¥ÀçµÇ¾î Çü¼ºµÇ¾î ÀÖ½À´Ï´Ù. ÁÖ¿ä ±â¾÷µéÀº CRISPR, TALEN, ¡ũ ÇΰŠ´ºÅ¬·¹¾ÆÁ¦(ZFN) ±â¹Ý Ä¡·áÁ¦¸¦ Àû±ØÀûÀ¸·Î °³¹ßÇϰí ÀÖÀ¸¸ç, ´Ù¾çÇÑ À¯Àü¼º Áúȯ°ú ¸¸¼ºÁúȯÀ» Ÿ°ÙÀ¸·Î Çϰí ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿ÀÅ×Å© ½ºÅ¸Æ®¾÷°ú ´ëÇü Á¦¾àȸ»ç¿ÍÀÇ Á¦ÈÞ´Â Àӻ󰳹߰ú ½ÂÀÎÀ» ¾Õ´ç±â±â À§ÇÑ ¸ñÀûÀ¸·Î Á¡Á¡ ´õ º¸Æíȵǰí ÀÖ½À´Ï´Ù. ÁÖ¸ñÇÒ ¸¸ÇÑ ÁøÀüÀ¸·Î´Â Ç÷¾× Áúȯ¿¡ ´ëÇÑ CRISPR ±â¹Ý Ä¡·á¹ý°ú ¾Ï¿¡ ´ëÇÑ CAR-T ¼¼Æ÷ °øÇÐ °øµ¿ °³¹ß Á¦ÈÞ µîÀÌ ÀÖ½À´Ï´Ù. Çмú ±â°üµµ Áß¿äÇÑ ¿ªÇÒÀ» ´ã´çÇϰí ÀÖÀ¸¸ç, Ãʱ⠴ܰèÀÇ ¿¬±¸¿Í µµ±¸ÀÇ °³¼±¿¡ ±â¿©ÇÏ°í ³ªÁß¿¡ Ä¡·á¿ëÀ¸·Î ¶óÀ̼¾½º¸¦ ºÎ¿©ÇÏ´Â µ¥ ±â¿©Çϰí ÀÖ½À´Ï´Ù. µ¶Á¡ ¶óÀ̼±½º °è¾à, ±¹Á¦ ½ÃÀå ÁøÃâ, GMP Áؼö Á¦Á¶ ½Ã¼³¿¡ ´ëÇÑ ÅõÀÚ¿Í °°Àº Àü·«Àû ÀÌ´Ï¼ÅÆ¼ºê´Â ¸ÂÃãÇü Ä¡·á¿Í ±Ùº»ÀûÀÎ Ä¡·á¹ý °³¹ß¿¡ ÁßÁ¡À» µÎ°í °æÀï ¿ìÀ§¸¦ È®º¸ÇÏ´Â µ¥ ÀÖ¾î ÇÙ½ÉÀûÀÎ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå À¯ÀüÀÚ ÆíÁý Ä¡·áÁ¦ ½ÃÀå °³¿ä
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå À¯ÀüÀÚ ÆíÁý Ä¡·áÁ¦ÀÇ ÁÖ¿ä ½ÃÀå µ¿Çâ
½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
½ÃÀå ±âȸ
½ÃÀå Àü¸Á µ¿Çâ
Á¦4Àå À¯ÀüÀÚ ÆíÁý Ä¡·áÁ¦ »ê¾÷ Á¶»ç
PEST ºÐ¼®
Porter's Five Forces ºÐ¼®
¼ºÀå Àü¸Á ¸ÅÇÎ
±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ© ºÐ¼®
Á¦5Àå À¯ÀüÀÚ ÆíÁý Ä¡·áÁ¦ ½ÃÀå : ³ô¾ÆÁö´Â ÁöÁ¤ÇÐÀû ±äÀåÀÇ ¿µÇâ
COVID-19 ÆÒµ¥¹ÍÀÇ ¿µÇâ
·¯½Ã¾Æ¡¤¿ìÅ©¶óÀ̳ª ÀüÀïÀÇ ¿µÇâ
Áßµ¿ ºÐÀïÀÇ ¿µÇâ
Á¦6Àå À¯ÀüÀÚ ÆíÁý Ä¡·áÁ¦ ½ÃÀå »óȲ
À¯ÀüÀÚ ÆíÁý Ä¡·áÁ¦ ½ÃÀå Á¡À¯À² ºÐ¼®(2024³â)
ÁÖ¿ä Á¦Á¶¾÷üº° ³»¿ª µ¥ÀÌÅÍ
±âÁ¸ ±â¾÷ ºÐ¼®
½ÅÈï ±â¾÷ ºÐ¼®
Á¦7Àå À¯ÀüÀÚ ÆíÁý Ä¡·áÁ¦ ½ÃÀå : ±â¼úº°
°³¿ä
ºÎ¹®º° Á¡À¯À² ºÐ¼® : ±â¼úº°
CRISPR
ZFN
TALEN
¿°±â ÆíÁý
RNA ÆíÁý
Á¦8Àå À¯ÀüÀÚ ÆíÁý Ä¡·áÁ¦ ½ÃÀå : °³¹ß ´Ü°èº°
°³¿ä
ºÎ¹®º° Á¡À¯À² ºÐ¼® : °³¹ß ´Ü°èº°
ÀüÀÓ»ó
Á¦I»ó
Á¦II»ó
Á¦III»ó
½ÂÀÎ ÈÄ
Á¦9Àå À¯ÀüÀÚ ÆíÁý Ä¡·áÁ¦ ½ÃÀå : Ä¡·á Á¾·ùº°
°³¿ä
ºÎ¹®º° Á¡À¯À² ºÐ¼® : Ä¡·á Á¾·ùº°
»ýü³» À¯ÀüÀÚ ÆíÁý
»ýü¿Ü À¯ÀüÀÚ ÆíÁý
Á¦10Àå À¯ÀüÀÚ ÆíÁý Ä¡·áÁ¦ ½ÃÀå : ÀûÀÀÁõº°
°³¿ä
ºÎ¹®º° Á¡À¯À² ºÐ¼® : ÀûÀÀÁõº°
Ç÷¾×Áúȯ
À¯Àü¼º Áúȯ(¿¹ : °â»ó ÀûÇ÷±¸Áõ, DMD)
¾Ï
°¨¿°Áõ
¾ÈÁúȯ
Á¦11Àå À¯ÀüÀÚ ÆíÁý Ä¡·áÁ¦ ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°
°³¿ä
ºÎ¹®º° Á¡À¯À² ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°
º´¿ø
Àü¹® Ŭ¸®´Ð
¿¬±¸±â°ü
¹ÙÀÌ¿ÀÀǾàǰ ±â¾÷
Á¦12Àå À¯ÀüÀÚ ÆíÁý Ä¡·áÁ¦ ½ÃÀå : Áö¿ªº°
ºÏ¹Ì
°³¿ä
ºÏ¹ÌÀÇ ÁÖ¿ä Á¦Á¶¾÷ü
¹Ì±¹
ij³ª´Ù
À¯·´
°³¿ä
À¯·´ÀÇ ÁÖ¿ä Á¦Á¶¾÷ü
µ¶ÀÏ
¿µ±¹
ÇÁ¶û½º
ÀÌÅ»¸®¾Æ
½ºÆäÀÎ
³×´ú¶õµå
½º¿þµ§
·¯½Ã¾Æ
Æú¶õµå
±âŸ
¾Æ½Ã¾ÆÅÂÆò¾ç(APAC)
°³¿ä
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÁÖ¿ä Á¦Á¶¾÷ü
Áß±¹
Àεµ
ÀϺ»
Çѱ¹
È£ÁÖ
Àεµ³×½Ã¾Æ
ű¹
Çʸ®ÇÉ
±âŸ
¶óƾ¾Æ¸Þ¸®Ä«(LATAM)
°³¿ä
¶óƾ¾Æ¸Þ¸®Ä«ÀÇ ÁÖ¿ä Á¦Á¶¾÷ü
ºê¶óÁú
¸ß½ÃÄÚ
¾Æ¸£ÇîÆ¼³ª
ÄÝ·Òºñ¾Æ
±âŸ
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
°³¿ä
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÁÖ¿ä Á¦Á¶¾÷ü
»ç¿ìµð¾Æ¶óºñ¾Æ
¾Æ¶ø¿¡¹Ì¸®Æ®
À̽º¶ó¿¤
Æ¢¸£Å°¿¹
¾ËÁ¦¸®
ÀÌÁýÆ®
±âŸ
Á¦13Àå ÁÖ¿ä º¥´õ ºÐ¼® : À¯ÀüÀÚ ÆíÁý Ä¡·áÁ¦ ¾÷°è
°æÀï ´ë½Ãº¸µå
±â¾÷ °³¿ä
ArsenalBio
Beam Therapeutics
Caribou Biosciences
CRISPR Therapeutics
Editas Medicine
EditForce
Excision BioTherapeutics
Graphite Bio
Homology Medicines
Intellia Therapeutics
LogicBio Therapeutics
Poseida Therapeutics
Precision BioSciences
Recombinetics
Sangamo Therapeutics
Verve Therapeutics
Others
Á¦14Àå AnalystViewÀÇ Àü¹æÀ§Àû ºÐ¼®
ksm
REPORT HIGHLIGHT
Gene Editing Therapeutics Market size was valued at US$ 11.13 Million in 2024, expanding at a CAGR of 147.20% from 2025 to 2032.
The Gene Editing Therapeutics Market centers on the development and commercialization of treatments that correct or modify genetic mutations at the DNA level to treat or potentially cure diseases. With increasing approvals for gene-editing therapies in rare and inherited disorders, the market is expanding into oncology and infectious diseases. In 2023, the U.S. FDA approved the first CRISPR-based therapy for sickle cell anemia, marking a major milestone in clinical gene editing. Technological innovations like base editing and prime editing are enhancing precision while minimizing off-target effects, making gene-editing tools safer for therapeutic use. However, high treatment costs, ethical concerns, and complex regulatory pathways continue to pose significant challenges to widespread adoption. Opportunities exist in the development of personalized medicine, targeting previously untreatable conditions, and expanding gene editing to common diseases, supported by increasing research funding from national health agencies and global biotech collaborations.
Gene Editing Therapeutics Market- Market Dynamics
Breakthrough clinical approvals and precision tools to boost therapeutic adoption
Breakthrough clinical approvals and precision tools are significantly boosting the adoption of gene editing therapeutics worldwide. The U.S. FDA's 2023 approval of the first CRISPR-based therapy for sickle cell disease, developed in partnership with Vertex Pharmaceuticals and CRISPR Therapeutics, marked a historic shift toward clinical application of gene editing. Simultaneously, the National Institutes of Health (NIH) has increased funding for precision genome engineering research, promoting tools like base editing and prime editing to correct mutations with fewer off-target effects. In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) has initiated accelerated review pathways for gene-editing therapies, aiming to bring advanced treatments to patients faster. These developments reflect a growing global emphasis on safe, efficient, and scalable therapeutic applications of gene editing, reinforcing its potential to transform the treatment of inherited disorders, cancers, and complex diseases.
Gene Editing Therapeutics Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 147.20% over the forecast period (2025-2032)
Based on Technology segmentation, CRISPR was predicted to show maximum market share in the year 2024
Based on Development Stage segmentation, Preclinical was the leading Development Stage in 2024
Based on Therapy Type segmentation, Ex Vivo Gene Editing was the leading Therapy Type in 2024
Based on Disease Indication segmentation, Genetic Disorders were the leading Disease Indication in 2024
Based on end user segmentation, Biopharma Companies was the leading end user in 2024
On the basis of region, North America was the leading revenue generator in 2024
Gene Editing Therapeutics Market- Segmentation Analysis:
The Global Gene Editing Therapeutics Market is segmented on the basis of Technology, Development Stage, Therapy Type, Disease Indication, End User, and Region.
The market is divided into five categories based on Technology: CRISPR, ZFN, TALEN, Base Editing, and RNA Editing. CRISPR leads due to its simplicity and high efficiency; ZFN offers specificity but requires complex design; TALEN is valued for targeting precision in gene knockout studies; base editing enables single-nucleotide changes; RNA editing allows transient modifications without altering DNA.
The market is divided into five categories based on Development Stage: Preclinical, Phase I, Phase II, Phase III, and Approved. Preclinical dominates with numerous candidates under investigation; Phase I focuses on safety profiling; Phase II explores therapeutic efficacy; Phase III involves large-scale validation across populations; Approved therapies mark successful transition from research to regulated treatment, gaining traction in rare genetic disorders.
Gene Editing Therapeutics Market- Geographical Insights
The Gene Editing Therapeutics Market exhibits strong regional dynamics, with North America at the forefront due to advanced biotech infrastructure, extensive clinical research activity, and supportive regulatory frameworks from agencies like the FDA. The U.S. leads in approvals and trials for CRISPR-based therapies, reinforced by substantial public and private funding. Europe follows closely, where countries such as the UK, Germany, and Switzerland are actively investing in precision medicine, and regulatory bodies like the EMA are increasingly receptive to innovative genetic treatments. The Asia-Pacific region is gaining traction, particularly in China and Japan, where government initiatives and biotech collaborations are accelerating gene editing research. China's active involvement in clinical trials and regulatory reforms is helping shape a competitive landscape. Latin America and the Middle East & and Africa are gradually entering the space through academic partnerships and pilot programs, focusing on capacity building and adapting regulatory models for future gene therapy integration.
Gene Editing Therapeutics Market- Competitive Landscape:
The competitive landscape of the Gene Editing Therapeutics Market is shaped by a mix of biotechnology firms, pharmaceutical companies, and academic research institutions striving to advance safe and effective gene-editing therapies. Leading players are actively developing CRISPR, TALEN, and zinc finger nuclease (ZFN)-based treatments, targeting a wide range of genetic and chronic diseases. Collaborations between biotech startups and large pharmaceutical companies are increasingly common, aimed at accelerating clinical development and regulatory approval. Notable advancements include partnerships to co-develop CRISPR-based therapies for blood disorders and CAR-T cell engineering for cancer. Academic institutions also play a vital role, contributing to early-stage research and tool refinement, which are later licensed for therapeutic use. Strategic initiatives such as exclusive licensing agreements, expansion into international markets, and investment in GMP-compliant manufacturing facilities are becoming central to gaining a competitive advantage, with a strong focus on developing personalized and curative therapies.
Recent Developments:
In May 2025, CRISPR Therapeutics and Sirius Therapeutics have announced a multi-target collaboration to develop novel siRNA therapies, including SRSD107 for thromboembolic disorders, aiming for best-in-class, long-acting gene-based treatments with infrequent dosing and improved patient outcomes.
In May 2025, NIH-supported researchers delivered the first personalized CRISPR gene-editing therapy to an infant with CPS1 deficiency. Using a rapid, customizable platform, the treatment corrected the genetic defect in liver cells within six months, marking a breakthrough for rare disease therapeutics.
In November 2023, Vertex and CRISPR Therapeutics received authorization for the world's first CRISPR-based gene editing therapy for sickle cell disease and beta thalassemia, marking a historic milestone in gene editing therapeutics and offering new hope for patients with these genetic disorders.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL GENE EDITING THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
ArsenalBio
Beam Therapeutics
Caribou Biosciences
CRISPR Therapeutics
Editas Medicine
EditForce
Excision BioTherapeutics
Graphite Bio
Homology Medicines
Intellia Therapeutics
LogicBio Therapeutics
Poseida Therapeutics
Precision BioSciences
Recombinetics
Sangamo Therapeutics
Verve Therapeutics
Others
GLOBAL GENE EDITING THERAPEUTICS MARKET, BY TECHNOLOGY- MARKET ANALYSIS, 2019 - 2032
CRISPR
ZFN
TALEN
Base Editing
RNA Editing
GLOBAL GENE EDITING THERAPEUTICS MARKET, BY DEVELOPMENT STAGE- MARKET ANALYSIS, 2019 - 2032
Preclinical
Phase I
Phase II
Phase III
Approved
GLOBAL GENE EDITING THERAPEUTICS MARKET, BY THERAPY TYPE- MARKET ANALYSIS, 2019 - 2032
In Vivo Gene Editing
Ex Vivo Gene Editing
GLOBAL GENE EDITING THERAPEUTICS MARKET, BY DISEASE INDICATION- MARKET ANALYSIS, 2019 - 2032
Hematologic Disorders
Genetic Disorders (e.g., Sickle Cell, DMD)
Cancer
Infectious Diseases
Eye Disorders
GLOBAL GENE EDITING THERAPEUTICS MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032
Hospitals
Specialty Clinics
Research Organizations
Biopharma Companies
GLOBAL GENE EDITING THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Rest of MEA
Table of Contents
1. Gene Editing Therapeutics Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Gene Editing Therapeutics Market Snippet by Technology
2.1.2. Gene Editing Therapeutics Market Snippet by Development Stage
2.1.3. Gene Editing Therapeutics Market Snippet by Therapy Type
2.1.4. Gene Editing Therapeutics Market Snippet by Disease Indication
2.1.5. Gene Editing Therapeutics Market Snippet by End User
2.1.6. Gene Editing Therapeutics Market Snippet by Country
2.1.7. Gene Editing Therapeutics Market Snippet by Region
2.2. Competitive Insights
3. Gene Editing Therapeutics Key Market Trends
3.1. Gene Editing Therapeutics Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Gene Editing Therapeutics Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Gene Editing Therapeutics Market Opportunities
3.4. Gene Editing Therapeutics Market Future Trends
4. Gene Editing Therapeutics Industry Study
4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Gene Editing Therapeutics Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Gene Editing Therapeutics Market Landscape
6.1. Gene Editing Therapeutics Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players' Analysis
6.2.2. Emerging Players' Analysis
7. Gene Editing Therapeutics Market - By Technology
7.1. Overview
7.1.1. Segment Share Analysis, By Technology, 2024 & 2032 (%)
7.1.2. CRISPR
7.1.3. ZFN
7.1.4. TALEN
7.1.5. Base Editing
7.1.6. RNA Editing
8. Gene Editing Therapeutics Market - By Development Stage
8.1. Overview
8.1.1. Segment Share Analysis, By Development Stage, 2024 & 2032 (%)
8.1.2. Preclinical
8.1.3. Phase I
8.1.4. Phase II
8.1.5. Phase III
8.1.6. Approved
9. Gene Editing Therapeutics Market - By Therapy Type
9.1. Overview
9.1.1. Segment Share Analysis, By Therapy Type, 2024 & 2032 (%)
9.1.2. In Vivo Gene Editing
9.1.3. Ex Vivo Gene Editing
10. Gene Editing Therapeutics Market - By Disease Indication
10.1. Overview
10.1.1. Segment Share Analysis, By Disease Indication, 2024 & 2032 (%)
10.1.2. Hematologic Disorders
10.1.3. Genetic Disorders (e.g., Sickle Cell, DMD)
10.1.4. Cancer
10.1.5. Infectious Diseases
10.1.6. Eye Disorders
11. Gene Editing Therapeutics Market - By End User
11.1. Overview
11.1.1. Segment Share Analysis, By End User, 2024 & 2032 (%)
11.1.2. Hospitals
11.1.3. Specialty Clinics
11.1.4. Research Organizations
11.1.5. Biopharma Companies
12. Gene Editing Therapeutics Market- By Geography
12.1. Introduction
12.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
12.2. North America
12.2.1. Overview
12.2.2. Gene Editing Therapeutics Key Manufacturers in North America
12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.2.4. North America Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.2.5. North America Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.2.6. North America Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.2.7. North America Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.2.8. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.2.9. U.S.
12.2.9.1. Overview
12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.2.9.3. U.S. Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.2.9.4. U.S. Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.2.9.5. U.S. Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.2.9.6. U.S. Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.2.9.7. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.2.10. Canada
12.2.10.1. Overview
12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.2.10.3. Canada Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.2.10.4. Canada Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.2.10.5. Canada Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.2.10.6. Canada Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.2.10.7. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3. Europe
12.3.1. Overview
12.3.2. Gene Editing Therapeutics Key Manufacturers in Europe
12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.3.4. Europe Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.3.5. Europe Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.3.6. Europe Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.3.7. Europe Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.3.8. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.9. Germany
12.3.9.1. Overview
12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.9.3. Germany Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.3.9.4. Germany Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.3.9.5. Germany Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.3.9.6. Germany Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.3.9.7. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.10. UK
12.3.10.1. Overview
12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.10.3. UK Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.3.10.4. UK Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.3.10.5. UK Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.3.10.6. UK Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.3.10.7. UK Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.11. France
12.3.11.1. Overview
12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.11.3. France Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.3.11.4. France Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.3.11.5. France Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.3.11.6. France Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.3.11.7. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.12. Italy
12.3.12.1. Overview
12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.12.3. Italy Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.3.12.4. Italy Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.3.12.5. Italy Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.3.12.6. Italy Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.3.12.7. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.13. Spain
12.3.13.1. Overview
12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.13.3. Spain Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.3.13.4. Spain Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.3.13.5. Spain Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.3.13.6. Spain Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.3.13.7. Spain Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.14. The Netherlands
12.3.14.1. Overview
12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.14.3. The Netherlands Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.3.14.4. The Netherlands Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.3.14.5. The Netherlands Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.3.14.6. The Netherlands Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.3.14.7. The Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.15. Sweden
12.3.15.1. Overview
12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.15.3. Sweden Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.3.15.4. Sweden Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.3.15.5. Sweden Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.3.15.6. Sweden Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.3.15.7. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.16. Russia
12.3.16.1. Overview
12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.16.3. Russia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.3.16.4. Russia Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.3.16.5. Russia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.3.16.6. Russia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.3.16.7. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.17. Poland
12.3.17.1. Overview
12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.17.3. Poland Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.3.17.4. Poland Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.3.17.5. Poland Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.3.17.6. Poland Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.3.17.7. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.18. Rest of Europe
12.3.18.1. Overview
12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.18.3. Rest of the Europe Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.3.18.4. Rest of the Europe Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.3.18.5. Rest of the Europe Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.3.18.6. Rest of the Europe Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.3.18.7. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4. Asia Pacific (APAC)
12.4.1. Overview
12.4.2. Gene Editing Therapeutics Key Manufacturers in Asia Pacific
12.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.4.4. APAC Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.4.5. APAC Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.4.6. APAC Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.4.7. APAC Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.4.8. APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.9. China
12.4.9.1. Overview
12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.9.3. China Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.4.9.4. China Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.4.9.5. China Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.4.9.6. China Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.4.9.7. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.10. India
12.4.10.1. Overview
12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.10.3. India Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.4.10.4. India Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.4.10.5. India Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.4.10.6. India Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.4.10.7. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.11. Japan
12.4.11.1. Overview
12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.11.3. Japan Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.4.11.4. Japan Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.4.11.5. Japan Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.4.11.6. Japan Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.4.11.7. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.12. South Korea
12.4.12.1. Overview
12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.12.3. South Korea Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.4.12.4. South Korea Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.4.12.5. South Korea Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.4.12.6. South Korea Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.4.12.7. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.13. Australia
12.4.13.1. Overview
12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.13.3. Australia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.4.13.4. Australia Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.4.13.5. Australia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.4.13.6. Australia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.4.13.7. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.14. Indonesia
12.4.14.1. Overview
12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.14.3. Indonesia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.4.14.4. Indonesia Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.4.14.5. Indonesia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.4.14.6. Indonesia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.4.14.7. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.15. Thailand
12.4.15.1. Overview
12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.15.3. Thailand Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.4.15.4. Thailand Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.4.15.5. Thailand Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.4.15.6. Thailand Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.4.15.7. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.16. Philippines
12.4.16.1. Overview
12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.16.3. Philippines Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.4.16.4. Philippines Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.4.16.5. Philippines Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.4.16.6. Philippines Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.4.16.7. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.17. Rest of APAC
12.4.17.1. Overview
12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.17.3. Rest of APAC Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.4.17.4. Rest of APAC Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.4.17.5. Rest of APAC Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.4.17.6. Rest of APAC Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.4.17.7. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5. Latin America (LATAM)
12.5.1. Overview
12.5.2. Gene Editing Therapeutics Key Manufacturers in Latin America
12.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.5.4. LATAM Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.5.5. LATAM Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.5.6. LATAM Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.5.7. LATAM Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.5.8. LATAM Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5.9. Brazil
12.5.9.1. Overview
12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.9.3. Brazil Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.5.9.4. Brazil Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.5.9.5. Brazil Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.5.9.6. Brazil Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.5.9.7. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5.10. Mexico
12.5.10.1. Overview
12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.10.3. Mexico Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.5.10.4. Mexico Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.5.10.5. Mexico Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.5.10.6. Mexico Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.5.10.7. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5.11. Argentina
12.5.11.1. Overview
12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.11.3. Argentina Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.5.11.4. Argentina Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.5.11.5. Argentina Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.5.11.6. Argentina Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.5.11.7. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5.12. Colombia
12.5.12.1. Overview
12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.12.3. Colombia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.5.12.4. Colombia Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.5.12.5. Colombia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.5.12.6. Colombia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.5.12.7. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5.13. Rest of LATAM
12.5.13.1. Overview
12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.13.3. Rest of LATAM Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.5.13.4. Rest of LATAM Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.5.13.5. Rest of LATAM Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.5.13.6. Rest of LATAM Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.5.13.7. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6. Middle East and Africa
12.6.1. Overview
12.6.2. Gene Editing Therapeutics Key Manufacturers in Middle East and Africa
12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.6.4. Middle East and Africa Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.6.5. Middle East and Africa Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.6.6. Middle East and Africa Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.6.7. Middle East and Africa Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.6.8. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.9. Saudi Arabia
12.6.9.1. Overview
12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.9.3. Saudi Arabia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.6.9.4. Saudi Arabia Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.6.9.5. Saudi Arabia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.6.9.6. Saudi Arabia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.6.9.7. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.10. United Arab Emirates
12.6.10.1. Overview
12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.10.3. United Arab Emirates Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.6.10.4. United Arab Emirates Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.6.10.5. United Arab Emirates Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.6.10.6. United Arab Emirates Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.6.10.7. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.11. Israel
12.6.11.1. Overview
12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.11.3. Israel Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.6.11.4. Israel Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.6.11.5. Israel Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.6.11.6. Israel Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.6.11.7. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.12. Turkey
12.6.12.1. Overview
12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.12.3. Turkey Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.6.12.4. Turkey Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.6.12.5. Turkey Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.6.12.6. Turkey Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.6.12.7. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.13. Algeria
12.6.13.1. Overview
12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.13.3. Algeria Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.6.13.4. Algeria Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.6.13.5. Algeria Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.6.13.6. Algeria Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.6.13.7. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.14. Egypt
12.6.14.1. Overview
12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.14.3. Egypt Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.6.14.4. Egypt Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.6.14.5. Egypt Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.6.14.6. Egypt Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.6.14.7. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.15. Rest of MEA
12.6.15.1. Overview
12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.15.3. Rest of MEA Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.6.15.4. Rest of MEA Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.6.15.5. Rest of MEA Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.6.15.6. Rest of MEA Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.6.15.7. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
13. Key Vendor Analysis- Gene Editing Therapeutics Industry
13.1. Competitive Dashboard
13.1.1. Competitive Benchmarking
13.1.2. Competitive Positioning
13.2. Company Profiles
13.2.1. ArsenalBio
13.2.2. Beam Therapeutics
13.2.3. Caribou Biosciences
13.2.4. CRISPR Therapeutics
13.2.5. Editas Medicine
13.2.6. EditForce
13.2.7. Excision BioTherapeutics
13.2.8. Graphite Bio
13.2.9. Homology Medicines
13.2.10. Intellia Therapeutics
13.2.11. LogicBio Therapeutics
13.2.12. Poseida Therapeutics
13.2.13. Precision BioSciences
13.2.14. Recombinetics
13.2.15. Sangamo Therapeutics
13.2.16. Verve Therapeutics
13.2.17. Others
14. 360 Degree Analyst View
15. Appendix
15.1. Research Methodology
15.2. References
15.3. Abbreviations
15.4. Disclaimer
15.5. Contact Us